Plexxikon signs deal with Roche for US co-promotion of Phase III melanoma candidate
This article was originally published in Scrip
Executive Summary
Plexxikon, the developer of PLX4032, which has shown striking investigational results as a novel oral treatment of the deadly skin cancer, metastatic melanoma, is exercising its right to co-promote the compound in the US alongside Roche's Genentech unit.